Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML) Meeting Abstract


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Levy, M. Y.; Estey, E. H.; Perl, A. E.; Kantarjian, H.; Earle, D.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML)
Meeting Title: 57th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 126
Issue: 23
Meeting Dates: 2015 Dec 5-8
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2015-12-03
Language: English
ACCESSION: WOS:000368021800051
PROVIDER: wos
Notes: Meeting Abstract: 3794 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos
MSK Authors
  1. Jae Hong Park
    125 Park
Related MSK Work